Table 4 Best response by study and cohort

From: Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

 

EGF100642

EGF104911

 

HER2 positive ( n =42)

HER2 negative ( n =22)

HER2 positive ( n =58)

Best response, n (%)

 CR

0

1 (5)

1 (2)

 PR

10 (24)

0

8 (14)

 SD

20 (48)

3 (14)

18 (31)

 PD

12 (29)

15 (68)

29 (50)

 NE

0

3 (14)

2 (3)

 CBR

16 (38)

1 (5)

11 (19)

  1. Abbreviations: CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease; NE=non-evaluable; CBR=clinical benefit rate (CR; PR; SD â©Ÿ24 weeks).
Back to article page